STOCK TITAN
  1. Home
  2. News
  3. BNR

Burning Rock Biotech Limited American Depositary Shares - BNR STOCK NEWS

Welcome to our dedicated page for Burning Rock Biotech American Depositary Shares news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech American Depositary Shares stock.

Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is a pioneering cancer diagnostics company headquartered in China, established in 2014. The company is dedicated to leveraging next-generation sequencing (NGS) technology to advance precision oncology. This innovative approach aids in the selection of cancer therapies and the early detection of cancer, enhancing treatment outcomes and patient care.

Burning Rock operates through three primary segments: Central laboratory business, In-hospital business, and Pharma research and development services. The central laboratory business generates the majority of the company’s revenue. The company’s suite of products includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, which provide comprehensive cancer profiling and support personalized treatment plans.

In a strategic move to comply with NASDAQ Listing Rules 5810(c)(3)(A), Burning Rock must meet the minimum bid price requirement by June 26, 2024. Should the company's ADSs maintain a closing bid price of at least US$1.00 for ten consecutive business days, NASDAQ will confirm compliance, closing the matter. Failing this, the company might be granted an additional 180-day period to meet the requirement.

Recently, Burning Rock announced an ADS Ratio Change, equivalent to a one-for-ten reverse ADS split, effective immediately. Certificate holders must surrender existing ADSs for the new ratio, while uncertificated ADSs will auto-adjust. This change is expected to proportionally increase the ADS price, although no guarantees are provided.

Burning Rock’s mission, “Guard Life via Science,” underscores its commitment to advancing cancer diagnostics and treatment through scientific innovation. The company continues to make significant strides in cancer early detection, moving beyond proof-of-concept R&D into clinical validation.

For more information, visit ir.brbiotech.com.

News

Burning Rock Announces ADS Ratio Change

Rhea-AI Summary
Burning Rock Biotech (BNR) has announced a significant change in the ratio of its American depositary shares (ADSs) to Class A ordinary shares, with one ADS now representing ten Class A ordinary shares. This move aims to enhance the company's capital structure and potentially attract more investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Burning Rock Biotech (BNR) reported financial results for Q4 and full year 2023, highlighting revenue declines, new contracts, and operational optimizations. Breakthrough designations for cancer detection tests, positive clinical trial results, and partnerships with pharma companies were key developments. Despite revenue decreases, the company aims for breakeven in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
earnings
-
News

Burning Rock Announces Receipt of Notification from NASDAQ

Rhea-AI Summary
Burning Rock Biotech Limited (BNR) received a notification from NASDAQ regarding its non-compliance with the minimum bid price requirement, giving the company until June 26, 2024, to regain compliance. The company's business operations are not affected by the notification, and it intends to take measures to meet the requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
none
News

Burning Rock Announces Results of 2023 Annual General Meeting

Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) announced the passing of all shareholder resolutions at the 2023 annual general meeting, including the ratification of the appointment of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending December 31, 2023, the re-election of three directors, and the authorization of directors to take necessary actions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
News

Burning Rock Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) reported financial results for the three months ended September 30, 2023. The company achieved significant milestones in therapy selection and minimal residual disease, received Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test, and entered into a Master Service Agreement in Oncology Companion Diagnostics with Boehringer Ingelheim. However, the company experienced a 17.5% decrease in revenues compared to the same period in 2022, with a net loss of RMB175.0 million (US$24.0 million) for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
earnings
-
News

Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023

Rhea-AI Summary
Burning Rock Biotech Limited (BNR) will hold its annual general meeting on December 20, 2023, to vote on the appointment of an auditor, re-election of directors, and authorization of necessary actions. Shareholders of record as of November 22, 2023, will be entitled to attend the meeting. The complete audited financial statements and report of auditors for the year ended December 31, 2022, are available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023

Rhea-AI Summary
Burning Rock Biotech (BNR) plans to release its unaudited financial results for Q3 2023 on November 30, 2023. The company will host a conference call to discuss the results and provide a live and archived webcast for investors. Please register in advance to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
earnings
-
News

Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics

Rhea-AI Summary
Burning Rock Biotech has signed a Master Service Agreement (MSA) with Boehringer Ingelheim in the field of oncology companion diagnostics. The partnership aims to advance clinical trials for Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, and develop companion diagnostic products in China. Brigimadlin has received approval for its Phase II clinical trial, offering new treatment options for patients with MDM2-amplified, TP53 wild-type cancers. Burning Rock will provide support for the research and development of brigimadlin and companion diagnostic assays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none
-
News

Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

Rhea-AI Summary
Burning Rock Biotech announces enrollment of CanCatch® in a 5-year study on MRD in lung cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
none
News

Burning Rock Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Burning Rock Biotech reports Q2 2023 financial results with revenues of RMB146.3 million, representing an 11.8% increase YoY. Gross profit increased by 21.6% to RMB100.4 million. Total value of new contracts for pharma services increased by 60% YoY to RMB88 million. Net loss decreased to RMB131.2 million from RMB262.1 million in Q2 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
earnings

FAQ

What is the current stock price of Burning Rock Biotech American Depositary Shares (BNR)?

The current stock price of Burning Rock Biotech American Depositary Shares (BNR) is $4.64 as of November 20, 2024.

What is the market cap of Burning Rock Biotech American Depositary Shares (BNR)?

The market cap of Burning Rock Biotech American Depositary Shares (BNR) is approximately 48.3M.

What is Burning Rock Biotech Limited?

Burning Rock Biotech Limited is a cancer diagnostics company that utilizes next-generation sequencing (NGS) technology for precision oncology.

What are the main business segments of Burning Rock?

Burning Rock operates through Central laboratory business, In-hospital business, and Pharma research and development services.

How does Burning Rock generate most of its revenue?

The majority of Burning Rock's revenue comes from its Central laboratory business.

What recent compliance measure did Burning Rock announce?

Burning Rock announced they must meet NASDAQ’s minimum bid price requirement by June 26, 2024, with a potential additional 180-day compliance period if needed.

What is the ADS Ratio Change for Burning Rock?

The ADS Ratio Change is a one-for-ten reverse ADS split, requiring certificate holders to exchange existing ADSs for new ones.

What products does Burning Rock offer?

Burning Rock's product portfolio includes Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

What is the mission of Burning Rock Biotech Limited?

Burning Rock's mission is to

Where can I find more information about Burning Rock?

More information is available on their investor relations website: ir.brbiotech.com.

What does the ADS ratio change mean for investors?

The ADS ratio change is expected to increase the ADS price proportionally, although there are no guarantees.

Are there any changes to Burning Rock's Class A ordinary shares?

There are no changes to the Company's Class A ordinary shares due to the ADS Ratio Change.

Stock BNR logo
Burning Rock Biotech Limited American Depositary Shares

Nasdaq:BNR

BNR Rankings

#4859 Ranked by Market Cap
N/A Ranked by Dividends

BNR Stock Data

48.32M
6.63M
0.04%
60.95%
0.82%
Diagnostics & Research
Healthcare
Link
United States of America
Guangzhou